Precision medicine made trials smarter. It also made recruitment harder.

“The window between diagnosis and treatment initiation can be as short as two to three weeks, so timing is key. Aperture addresses this by notifying trial teams immediately when eligible patients are identified.”

Featured in Drug Discovery & Development, Brian Buntz covers how Proscia Aperture, designed to surface trial-eligible patients at the moment of diagnosis, is addressing the most critical challenges in precision medicine.